SCHEMBL322329

SCHEMBL322329

N#Cc1cc(Br)cnc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.54
KMT2A Q03164 3/20 0.54
CSNK1A1 P48729 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
DYRK1A Q13627 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
IDO1 P14902 1/20 0.39
ABL1 P00519 2/20 0.39
KDR P35968 2/20 0.39
CHEK1 O14757 2/20 0.37
MEN1 O00255 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217691 1.00 HTT (0.54) HTTKMT2ACSNK1A1CLK4CYP11B1
SCHEMBL29174253 0.84 TNKS (0.47) HTTKMT2ACSNK1A1CLK4CYP11B1
SCHEMBL10017418 0.79 KMT2A (0.54) HTTKMT2ACSNK1A1CLK4DYRK1A
SCHEMBL7898980 0.78 HTT (0.44) HTTCSNK1A1CLK4CYP11B1CYP11B2
SCHEMBL245286 0.77 HTT (0.62) HTTCSNK1A1CLK4CYP11B1CYP11B2
SCHEMBL2040558 0.76 KMT2A (0.50) HTTKMT2ACSNK1A1CLK4DYRK1A
SCHEMBL20319388 0.76 HTT (0.37) HTTKMT2ACSNK1A1CLK4CYP11B1
SCHEMBL17486279 0.75 CYP11B2 (0.37) HTTKMT2ACYP11B1CYP11B2DYRK1A
SCHEMBL459834 0.75 CHEK1 (0.37) HTTKMT2ACYP11B1CYP11B2ABL1
SCHEMBL1164261 0.75 ALDH1A1 (0.53) HTTKMT2ACSNK1A1CLK4CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492194-B2 HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-09 US disclosed
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists Nimbus Saturn, Inc. (US) 2025-11-11 US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 US disclosed
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 EP disclosed
WO-2025131978-A1 DRUG-LINKER REAGENTS FOR CONJUGATION NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 WO disclosed
EP-3947366-B1 HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
WO-2025101914-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS MEKANISTIC THERAPEUTICS LLC (US) 2025-05-15 WO disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-09-28 US disclosed
WO-2006099972-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-09-28 WO disclosed
US-20060183908-A1 inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics AFFINIUM PHARMACEUTICALS, INC. (CA) 2006-08-17 US disclosed
US-20060142265-A1 Compositions comprising multiple bioactive agents, and methods of using the same AFFINIUM PHARMACEUTICALS, INC. (CA) 2006-06-29 US disclosed
EP-1608377-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS Affinium Pharmaceuticals, Inc. (CA) 2005-12-28 EP disclosed
EP-1575951-A1 HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY Affinium Pharmaceuticals, Inc. (CA) 2005-09-21 EP disclosed
WO-2004082586-A2 PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS AFFINIUM PHARMACEUTICALS, INC. (US) 2004-09-30 WO disclosed
WO-2004052890-A1 HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY AFFINIUM PHARMACEUTICALS, INC. (CA) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, TPMT, ACAT1 HTT 1390/4885KMT2A 1079/4885CSNK1A1 1086/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 HTT 4666/4885KMT2A 1382/4885CSNK1A1 1360/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HTT 1112/4885KMT2A 440/4885CSNK1A1 194/4885
US-20060183908-A1 inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics AADAC, AZI2, DCXR HTT 4455/4885KMT2A 752/4885CSNK1A1 2594/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B HTT 2728/4885KMT2A 684/4885CSNK1A1 180/4885
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists PDXK, HIPK1, HIPK3 HTT 1365/4885KMT2A 2379/4885CSNK1A1 146/4885
US-20060142265-A1 Compositions comprising multiple bioactive agents, and methods of using the same DBI, SERPINB1, CTSF HTT 2878/4885KMT2A 4353/4885CSNK1A1 520/4885
US-20250326748-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 HTT 1075/4885KMT2A 3214/4885CSNK1A1 1236/4885
US-12492194-B2 HPK1 inhibitors PGK1, PCK1, PDXK HTT 1471/4885KMT2A 2493/4885CSNK1A1 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.